[Skip to Content]
[Skip to Content Landing]
Invited Commentary
November 2015

Precision Medicine in Breast Cancer Care: An Early Glimpse of Impact

Author Affiliations
  • 1Department of Medicine, Stanford University School of Medicine, Stanford, California
  • 2Department of Health Research and Policy, Stanford University School of Medicine, Stanford, California
  • 3Department of Systems, Populations and Leadership, University of Michigan School of Nursing, Ann Arbor
  • 4Institute for Healthcare Policy and Innovation, University of Michigan School of Nursing, Ann Arbor
JAMA Oncol. 2015;1(8):1109-1110. doi:10.1001/jamaoncol.2015.2719

Precision medicine—the concept of targeting therapy to a patient’s unique genetic or other relevant characteristics—occupies a prominent place on the national agenda.1 No condition demonstrates recent efforts toward precision medicine more clearly than cancer, and particularly breast cancer. After a decade of molecular subtyping, increasingly comprehensive genomic tests are emerging into breast cancer care. The 21-gene recurrence score (RS) assay has led the way in clinical implementation and thus offers an early opportunity to measure the impact of precision medicine on cancer treatment.

×